Synaptogenix Future Growth

Future criteria checks 0/6

Synaptogenix's earnings are forecast to decline at 32.9% per annum. EPS is expected to grow by 8% per annum.

Key information

-32.9%

Earnings growth rate

8.0%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	11 Jul 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:SNPX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-21	N/A	N/A	1
12/31/2025	N/A	-13	N/A	N/A	1
12/31/2024	N/A	-8	N/A	N/A	1
9/30/2024	N/A	-9	-5	-5	N/A
6/30/2024	N/A	-3	-5	-5	N/A
3/31/2024	N/A	-12	-5	-5	N/A
12/31/2023	N/A	-14	-5	-5	N/A
9/30/2023	N/A	-8	-7	-7	N/A
6/30/2023	N/A	-11	-8	-8	N/A
3/31/2023	N/A	-4	-9	-9	N/A
12/31/2022	N/A	-6	-11	-11	N/A
9/30/2022	N/A	-14	-10	-10	N/A
6/30/2022	N/A	-14	-9	-9	N/A
3/31/2022	N/A	-13	-9	-9	N/A
12/31/2021	N/A	-13	-9	-9	N/A
9/30/2021	N/A	-14	-8	-8	N/A
6/30/2021	N/A	-15	-10	-10	N/A
3/31/2021	N/A	-16	-10	-10	N/A
12/31/2020	N/A	-15	-8	-8	N/A
9/30/2020	N/A	-12	-8	-8	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNPX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNPX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNPX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SNPX's revenue is forecast to grow faster than the US market.

High Growth Revenue: SNPX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SNPX's Return on Equity is forecast to be high in 3 years time

Synaptogenix Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Synaptogenix, Inc., Annual General Meeting, Dec 06, 2024

Insufficient new directors

Synaptogenix, Inc. announced that it has received $3.207 million in funding

Synaptogenix, Inc. announced a financing transaction

New major risk - Revenue and earnings growth

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix, Inc. (NasdaqCM:SNPX) acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.

New major risk - Share price stability

Synaptogenix, Inc., Annual General Meeting, Dec 20, 2023

New major risk - Shareholder dilution

New minor risk - Share price stability

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix, Inc. announced that it has received $15 million in funding

Synaptogenix, Inc. announced that it expects to receive $15 million in funding

We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth

Synaptogenix, Inc., Annual General Meeting, Oct 11, 2022

Synaptogenix, Inc. Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Synaptogenix, Inc. announced that it has received $12.477342 million in funding

President recently bought US$83k worth of stock

Synaptogenix, Inc. announced that it expects to receive $12.499998 million in funding

Synaptogenix: The Next Big Thing In Alzheimer's

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update

Synaptogenix provides update on phase 2b Alzheimer's disease trial

We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate

Synaptogenix, Inc. announced that it has received $14.0033 million in funding

Synaptogenix Announces Licensing Agreement with Stanford University; and Supply Agreement with Bryologyx, Inc

Synaptogenix announced that it expects to receive $14 million in funding

Synaptogenix Inc Announces CEO Changes

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies